Introduction

November 2025

Transforming Antivirals: Therapeutics for Broad Spectrum of Viruses

Novel, First-in-Class Approach

Allosteric, small molecule SIRT2 modulators targeting host cells to suppress viral infections and prevent drug-resistance

Broad Spectrum Applicability

SIRT2 modulation shifts metabolic reprogramming that can target a broad spectrum of pathogens and address conditions beyond infectious disease

Strategic Drug Development Plan

EV-100 is a clinic-ready asset poised to rapidly generate proof-of-concept data and derisk SIRT2-centered platform

Led By Team of Experts

Founded by established drug development leaders, backed by renowned scientific advisors and significant non-dilutive funding

evrys bio

SIRT2 Regulates Metabolic Reprogramming During Infection

Sirtuins are NAD⁺-dependent deacylases that play key roles in regulating various cellular processes



- Metabolic homeostasis/ reprogramming
- Carbon utilization
- Energy production
- Signal transduction

In low nutrient cellular environments, such as during a viral infection, NAD⁺ levels increase which upregulates SIRT2 activity



Metabolic enzymes Signaling proteins → Viral replication

SIRT2 modulation shifts metabolic reprogramming in the host cell to create a cellular environment unfavorable to any virus



Disrupted viral metabolic reprogramming → Viral replication



NAD⁺: nicotinamide adenine dinucleotide; NAM: nicotinamide; AADPR: acetyl-ADP-ribose.

evrys bio

Small Molecule Platform Enabling Fine-Tuning of SIRT2 Modulation

Allosteric	Modulator	Simultaneous
• Allosteric (i.e., non-competitive) inhibition means SIRT2 function is not completely turned off, potentially leading to safer drugs • Drug effects cannot be mimicked by genetic mutation • Requires lower dosing to confer effects comparable to a competitive inhibitor	• Platform can produce small molecules with unique binding properties adapted to different therapeutic areas • Various “flavors” of SIRT2 modulators can fine-tune metabolic reprogramming and become uniquely optimized against specific viral profiles	• SIRT2 modulation shifts metabolic reprogramming in the host cell to create a cellular environment unfavorable to any virus • Unique, broad-spectrum ability to treat multiple viruses simultaneously contrasts with currently available and traditional, “one-virus one-drug” approach

evrys bio

Pipeline Designed to Rapidly Generate Proof-of-Concept Data

Program	Indication	Drug Discovery	Preclinical Studies	IND-Enabling Studies	Clinical Trials	Status
EV-100	Opportunistic Infections in Transplant Setting					• Ready to finish IND-enabling studies in 5 months with additional funding • Potential IND filing and Phase 1 clinical trial initiation by Q2 2026
EV-200	Chronic Hepatitis B					• Running additional preclinical studies • Potential to initiate IND-enabling studies in 2027 with additional funding
EV-300	Medical Countermeasure for RNA Viruses					• Funded by DTRA • Evrys retains commercialization rights • Plan is to initiate IND-enabling or Animal Rule studies in Q4 2026
Exploratory Programs	Tuberculosis, Oncology, etc.					• Collaboration with the TB Alliance, animal proof-of-concept data obtained

HBV: hepatitis B virus; IND: Investigational New Drug; FIH: first-in-human; DTRA: Defense Threat Reduction Agency.

evrys bio

Evrys Bio Today: Advancing First-in-Class SIRT2 Modulators

At the cusp of clinical value inflection:

- Raised over $46.4M to date through private financing and government contracts
- Further $14.8M from grants and contracts for EV-300 program pending achievement of specific milestones
- Strong translational science already established around first-in-class mechanism
- SIRT2 modulation has broad spectrum applicability across infectious diseases and beyond
- Strong IP protection around platform

IP: intellectual property; IND: Investigational New Drug.